Navigation Links
Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor Ian Meredith, M.D., Monash Medical Centre, Melbourne, Australia, on Tuesday presented positive nine-month results from the Medtronic RESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain, with data showing a low number of adverse cardiac events and no protocol-defined stent thrombosis. The next-generation Medtronic (NYSE:MDT) Endeavor(R) Resolute drug-eluting stent system with new BioLinx(TM) polymer is designed to address the special needs of patients who have complex medical conditions and is engineered to match the duration of drug delivery with the longer healing duration often required by these patients.

In clinical results at nine months, the Endeavor RESOLUTE trial showed no Target Lesion Revascularization (TLR), no Target Vessel Revascularization (TVR) and a Major Adverse Cardiac Event (MACE) rate of just 7.0%. Of the trial's 130 patients, 129 (99.2%) received clinical follow-up, and 95 had angiographic follow-up. In-stent late lumen loss, the study's primary endpoint, was 0.22 mm, while in-segment late loss was 0.12 mm. In-stent Angiographic Binary Restenosis (ABR) was 1.0% percent and in-segment ABR was 2.1%.

"What is most impressive about these results is that they occurred in a patient population with complex and challenging characteristics," said Dr. Meredith, the principal investigator of the trial, noting that the average lesion length in the RESOLUTE trial was 15.5 mm and nearly 82% of enrolled patients were classified as having challenging B2/C lesions. "The RESOLUTE trial enrolled a high percentage of patients with lesions that are difficult to treat, including small vessels and long lesions, and these results are extremely promising. Zotarolimus continues to be a very potent drug in preventing restenosis while the new BioLinx polymer appears to be delivering the drug as intended."

Endeavor Resolute leverage
'"/>




Page: 1 2 3

Related medicine technology :

1. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
2. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
3. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:9/30/2014)... , September 30, 2014 ... report the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, ... Kits, and Reagents], Application (Immunology, Oncology) & ... 2019", published by MarketsandMarkets, provides a detailed ... opportunities, current market trends, and strategies impacting ...
(Date:9/30/2014)... ANGELES , Sept. 30, 2014   Easy ... shopping destination , today announced that it now offers ... . AirSense CPAPs are the first sleep apnea therapy ... it simple and easy to track and share real-time ... overall effectiveness of their CPAP therapy.  In addition, the ...
(Date:9/30/2014)... , Sept. 30, 2014 The Chinese ... ageing population and rise in the incidence of lifestyle ... wounds and in affordability of better quality of wound ... care market. Universal coverage of public health insurance schemes ... further stimulate demand. Based on the findings of primary ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4China Wound Care Market 2China Wound Care Market 3
... A partnership announced today between Medical City Hospital and Dallas Fire-Rescue ... technology, as Medical City recently helped outfit all DFR rescue units ... , , ... a unique combination of web, broadband and medical technology, will drastically ...
... and HAMILTON, Bermuda , April 30 Celtic ... the biotechnology and pharmaceutical industries, announced today the enrolment of the first ... for the topical treatment of onychomycosis (also known as a fungal nail ... This Phase ...
Cached Medicine Technology:Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 2Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 3Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 4Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 5Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 2Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 3Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 4
(Date:10/1/2014)... Fredericton, NB (PRWEB) October 01, 2014 Indosoft, ... software Q-Suite, announces that it has added support ... Both Sangoma and Indosoft have a history ... industry. Sangoma's patent-pending technology offers a significant benefit to ... with AMD that is now available to users of Q-Suite. ...
(Date:10/1/2014)... MI (PRWEB) October 01, 2014 To help ... wellness center , Cutler Integrative Medicine, is detailing several tips ... , According to Dr. Cutler, women should start ... quality time for yourself that will help ‘center’ yourself for ... of stress,” he says. , Other health and fitness ...
(Date:9/30/2014)... at the same time could stop them from becoming ... Cancer Research * today (Wednesday). , ... funded by MedImmune, the global biologics research and development ... combining the two treatments helped the immune system hunt ... the initial radiotherapy in mice with breast, skin and ...
(Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 ... put the brakes on motherhood. And for many young women, ... new research suggests. Women in their early 20s appear ... tough economic times. But, according to the new study, that ... 40s and beyond. The findings suggest that higher unemployment ...
Breaking Medicine News(10 mins):Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Immunotherapy could stop resistance to radiotherapy 2Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3
... criticized Advanced Cells Therapeutics, which provided stem cell therapy for ... better than conventional treatments and her illness has not improved. ... Bryson said, "I'm back to where I was before the ... hope it was going to work and it didn't. I ...
... Australians live longer but with more disabilities among the aged. While ... in 1988, more people are suffering disabilities later in life, according ... ,Life expectancy for non-Indigenous Australian men has increased by ... 2003 can expect to live up to 77 and women up ...
... of Punjab and Haryana - will soon have 20 condom ... ,The machines will be installed by the state AIDS ... operate, insure and refill these machines, an official spokesman said. ... men's toilets at various places. ,The points identified ...
... may result from the body overshooting as it tries ... suggests new research// from the University of Massachusetts Amherst ... to a different time zone, the researchers recommend advancing ... allowing the body’s clocks to remain coordinated. The work ...
... results of a Canadian study, a multivitamin pill should ... to reduce risks of having a child with birth ... possibility of a wide range of severe birth defects ... hydrocephalus, heart malformations, truncated or missing limbs, urinary-tract abnormalities ...
... have a deleterious effect on young, developing brains, according ... toddlers is linked to lower IQ scores later in ... problems like diabetes, high cholesterol and hypertension is a ... professor of pediatric genetics at the University of Florida ...
Cached Medicine News:Health News:Model of Internal Clocks Reveals How Jet Lag Disrupts the System 2Health News:Model of Internal Clocks Reveals How Jet Lag Disrupts the System 3Health News:Prenatal multivitamins reduce birth defects 2Health News:Prenatal multivitamins reduce birth defects 3Health News:IQ of Toddlers Affected by Excess weight 2
... The pause of a heartbeat. The ... of rhythmic breathing. These vital signs are ... check. DeRoyals line of Temperature Monitoring products ... the information needed to provide the most ...
... pause of a heartbeat. The bodys warmth ... breathing. These vital signs are yours to ... line of Temperature Monitoring products helps you ... needed to provide the most comfortable and ...
... is a portable, compact, lightweight system with ... emitting the same intensity (50 mW/cm) of ... smaller treatment area (30 cm). Excilite- possesses ... satisfy the most demanding professional users. The ...
... Smart 1064 is a laser system with ... versions with maximum continuous intensities of either 60 ... valid ally in all-mini-invasive surgical techniques. This laser ... it is the most requested from hospitals and ...
Medicine Products: